Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study

Masaki Shiota,Motonobu Nakamura,Akira Yokomizo,Toshihisa Tomoda,Naotaka Sakamoto,Narihito Seki,Shuji Hasegawa,Takakazu Yunoki,Masahiko Harano,Kentaro Kuroiwa,Masatoshi Eto

Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study

2019

Masaki Shiota
Motonobu Nakamura
Akira Yokomizo
Toshihisa Tomoda
Naotaka Sakamoto
Narihito Seki
Shuji Hasegawa
Takakazu Yunoki
Masahiko Harano
Kentaro Kuroiwa
Masatoshi Eto

Objective This study aimed to reveal the efficacy and safety profiles of 4-weekly cabazitaxel in patients with castration-resistant prostate cancer (CRPC).

Keywords:

Prostate cancer
Castration
Cabazitaxel
Pharmacology
Oncology
Adverse effect
Docetaxel
Internal medicine
Medicine
Interquartile range
Regimen
Confidence interval
Hazard ratio

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations